Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:10018-10018
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Widemann Brigitte C.¹,Marcus Leigh Jessica²,Fisher Michael J.³,Weiss Brian D.⁴,Kim AeRang⁵,Dombi Eva⁶,Baldwin Andrea⁷,Whitcomb Patricia⁷,Martin Staci⁷,Gillespie Andrea⁷,Doyle Austin⁸

Affiliation:

1. Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

2. Children's National Medical Center, Washington, MD

3. Children's Hospital, Philadelphia, PA

4. Cincinnati Children's Hospital Medical Center, Cincinnati, OH

5. Children's National Medical Center, Washington, DC

6. National Cancer Institute, Bethesda, MD

7. NCI, Bethesda, MD

8. National Cancer Institute, Rockville, MD

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.10018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications;Cancers;2022-10-29

2. Neurofibromatosis I and II;Neurocutaneous Disorders;2022

3. Phakomatosen;Pädiatrische Neurochirurgie;2018

4. Understanding and targeting resistance mechanisms in NSCLC;Nature Reviews Cancer;2017-10-25

5. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials;British Journal of Clinical Pharmacology;2017-09-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3